Mirae Company’s First ‘RevoEye’ Installation at Gippeum Hospital Achieves 100 Robot-Assisted Surgeries

[Asia Economy Reporter Jang Hyowon] Gippeum Hospital, which introduced the laparoscopic surgical robot ‘Revo-i’ from Mirae Company (CEO Kim Jungoo), has achieved 100 cases of robotic surgery for indications such as cholecystectomy and appendectomy.

Gippeum Hospital, specializing in surgical procedures such as hernia, gallstones, and appendicitis (acute appendicitis), has rapidly increased its robotic surgery cases since adopting Revo-i, solidifying its position as a hospital specialized in robotic surgery.

Through the Revo-i robotic surgeries performed at Gippeum Hospital, surgeons can operate with a high-resolution 3D screen magnified up to 15 times compared to conventional laparoscopic surgery, enabling more precise and delicate procedures. Additionally, there has been not a single case of infection or postoperative complications following cholecystectomy to date, demonstrating Revo-i’s excellent performance and stability.

CEO Kim Jung-gu of Mirae Company (left) is presenting a commemorative plaque for 100 Revo AI surgeries to Chief Director Kang Yoon-sik of Gippeum Hospital.

Yunsik Kang, Director of Gippeum Hospital, stated, “We have surpassed 100 cases of Revo-i laparoscopic robotic surgery without a single surgical complication. Above all, the surgical outcomes are good, resulting in high patient satisfaction.”

Jinwoo Lee, Head of the Robotic Surgery Department at Gippeum Hospital, said, “The greatest strength of Revo-i lies in its convenience, such as promptly reflecting improvements in robotic surgery and providing rapid maintenance support. It also has an advantage in terms of cost, so for hospitals considering the introduction of surgical robots, Revo-i would be a good alternative.”

Hogeun Lee, Executive Director of the Surgical Robot Division at Mirae Company, explained, “Since introducing Revo-i last November at Busan Queens Park Women’s Specialized Hospital, it has been actively applied to gynecological surgeries such as hysterectomy, ovarian cystectomy, myomectomy, and oophorectomy.”

He added, “Within just four months of introduction, 23 cases of various gynecological robotic surgeries have been achieved, rapidly accumulating robotic surgery cases and proving the effectiveness of Revo-i surgeries in gynecology.”

Furthermore, he stated, “We will focus our marketing capabilities to expand the supply of Revo-i from tertiary general hospitals to medium and large hospitals, and continuously upgrade Revo-i through exchanges with medical staff. We will do our best to ensure that more patients, medical professionals, and hospitals can receive advanced medical services.”

This content was produced with the assistance of AI translation services.